Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience

Introduction Dose reductions are often required to avoid toxicity in combination therapy for advanced cancers, but information on appropriate dose reductions in renal dysfunction is lacking. This study assessed dose reductions of renally cleared oncology agents given in combination therapy in the se...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikanjam, Mina, Wing, Jason, Capparelli, Edmund, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Nephrology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349570/
https://www.ncbi.nlm.nih.gov/pubmed/30705793
http://dx.doi.org/10.7759/cureus.3634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349570/
https://www.ncbi.nlm.nih.gov/pubmed/30705793
http://dx.doi.org/10.7759/cureus.3634

Ejemplares similares